Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review.

Literature DB >> 8638282

Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review.

Abstract

Orthoclone OKT3 is a very powerful immunosuppressive drug marketed by Laboratory Cilag and the first monoclonal murine antibody to become available for therapy in humans. It is indicated in acute allograft rejection treatment and its side-effects are strongly linked with its mechanism of action, ORT/OKT3 is an Ig2a immunoglobulin produced by hybridoma technique that recognizes, binds and blocks the CD3 complex of the T-cell receptor. Two types of side-effects may occur that are either the consequences of overimmunosuppression or activation of immune system, since ORT/OKT3 behaves as a foreign antigen. This report is a bibliographic review of the suspected side-effects of this product.

Entities: Chemical Species

Mesh：

Substances：

Year: 1995 PMID： 8638282 DOI： 10.1016/0300-483x(95)03123-w

Source DB: PubMed Journal: Toxicology ISSN： 0300-483X Impact factor: 4.221

Keyword Cloud
Cited

37 in total

1. Crystal structure of the human T cell receptor CD3 epsilon gamma heterodimer complexed to the therapeutic mAb OKT3.

Authors: Lars Kjer-Nielsen; Michelle A Dunstone; Lyudmila Kostenko; Lauren K Ely; Travis Beddoe; Nicole A Mifsud; Anthony W Purcell; Andrew G Brooks; James McCluskey; Jamie Rossjohn
Journal: Proc Natl Acad Sci U S A Date: 2004-05-10 Impact factor: 11.205

Review 2. Have we overestimated the benefit of human(ized) antibodies?

Authors: Daniel R Getts; Meghann T Getts; Derrick P McCarthy; Emily M L Chastain; Stephen D Miller
Journal: MAbs Date: 2010-11-01 Impact factor: 5.857

3. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

Authors: Richard A Morgan; James C Yang; Mio Kitano; Mark E Dudley; Carolyn M Laurencot; Steven A Rosenberg
Journal: Mol Ther Date: 2010-02-23 Impact factor: 11.454

Review 4. The birth pangs of monoclonal antibody therapeutics: the failure and legacy of Centoxin.

Authors: Lara Marks
Journal: MAbs Date: 2012-04-26 Impact factor: 5.857

5. Crystallization and preliminary X-ray structural studies of a high-affinity CD8alphaalpha co-receptor to pMHC.

Authors: David K Cole; Pierre J Rizkallah; Malkit Sami; Nikolai M Lissin; Feng Gao; John I Bell; Jonathan M Boulter; Meir Glick; Anne Lise Vuidepot; Bent K Jakobsen; George F Gao
Journal: Acta Crystallogr Sect F Struct Biol Cryst Commun Date: 2005-02-12

Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review.

1. Crystal structure of the human T cell receptor CD3 epsilon gamma heterodimer complexed to the therapeutic mAb OKT3.

Review 2. Have we overestimated the benefit of human(ized) antibodies?

3. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

Review 4. The birth pangs of monoclonal antibody therapeutics: the failure and legacy of Centoxin.

5. Crystallization and preliminary X-ray structural studies of a high-affinity CD8alphaalpha co-receptor to pMHC.

Review 6. Infectious complications associated with monoclonal antibodies and related small molecules.

Review 7. Immunotoxicity of monoclonal antibodies.

8. Optimization of the crystallizability of a single-chain antibody fragment.

9. Emerging trends and new developments in monoclonal antibodies: A scientometric analysis (1980-2016).

10. Functional characterization of N297A, a murine surrogate for low-Fc binding anti-human CD3 antibodies.